NeuroSense Therapeutics Ltd

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company's lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023 CAMBRIDGE, Mass. , Sept. 29, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference

Acumen Pharmaceuticals

Alzamend Neuro

Ginkgo Bioworks Holdings

Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes

Pharmacokineticic (PK) profile of PrimeC supports the formulation's extended release properties, as the active components are released simultaneously CAMBRIDGE, Mass. , Sept. 28, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US

PrimeC is safe and tolerable at over 4x the maximal clinical dose Data support current Phase IIb PARADIGM study design, new PrimeC formulation, and potential favorable clinical trial outcome CAMBRIDGE, Mass. , Sept. 20, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial

Groundbreaking ALS biomarker research: Marks the first publication of NeuroSense's novel biomarker results demonstrating PrimeC's effect on ALS related hallmarks PrimeC showed a statistically significant impact on key disease-related biomarkers including TDP-43, which increases with disease progression, and LC3, a key autophagy marker   Based on successful Phase IIa results, NeuroSense commenced PARADIGM, a Phase IIb clinical trial in May 2022 CAMBRIDGE, Mass., Sept. 19, 2022 /PRNewswire/ --  NeuroSense Therapeutics Ltd.

NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

CAMBRIDGE, Mass. , Aug. 31, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update

- NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments - NeuroSense's CEO to present at EverythingALS's Expert Talk Series on August 3, 2022; To listen to Mr. Ben-Noon's presentation register here: LINK LOS ALTOS, Calif.

NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study

NeuraLight's platform technology uses computer vision, artificial intelligence (AI), deep learning algorithms, and machine learning (ML) to identify and track oculometric digital biomarkers to transform clinical development, diagnostics, and precision medicine in neurology The NeuroSense-NeuraLight collaboration entails sharing and tracking patient data to advance the identification and use of ALS digital biomarkers CAMBRIDGE, Mass., AUSTIN, TX, and TEL AVIV, Israel , July 28, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML

View video here: https://youtu.be/KCT2wzOqmNo CAMBRIDGE, Mass. , July 18, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics CEO Provides Key Corporate Update Video

Chiasma

OXFORD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--SpyBiotech has appointed Mark Leuchtenberger as its CEO. Sumi Biswas, the company's co-founder, remains President and a Director and becomes CSO.

SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

NRSN stock is on the move in the wake of encouraging clinical results for a novel drug combination to treat Alzheimer's disease. The post Why Is NeuroSense (NRSN) Stock Up 35% Today?

Why Is NeuroSense (NRSN) Stock Up 35% Today?

Ardelyx

Revelation Biosciences

Penny stocks for your watch list with the stock market down today. The post 3 Penny Stocks To Watch While The Stock Market Is Down appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Watch While The Stock Market Is Down

NeuroSense Therapeutics Ltd (NASDAQ: NRSN) has announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimer's disease (AD). Earlier this week, NeuroSense reported results from a stage III ALS Biomarker study evaluating.

NeuroSense Shares Surge On Encouraging Data From Alzheimer's-Associated Biomarker Study

Biomarkers show the potential of NeuroSense's combination drug CogniC to treat Alzheimer's disease CogniC is expected to advance into clinical trials in 2023 CAMBRIDGE, Mass. , June 30, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study

Brickell Biotech Inc

Trevi Therapeutics Inc

Penny stocks to buy or avoid right now? You decide after seeing the latest updates from 3 companies.

3 Penny Stocks To Watch After GDP Report

Toughbuilt Industries Inc

Zomedica

Check these three penny stocks out right now The post Best Penny Stocks to Buy as June Ends? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy as June Ends? 3 to Watch

NRSN stock is getting plenty of attention today and a bid to the tune of more than 70% in the wake of positive clinical results. The post NeuroSense Therapeutics (NRSN) Stock Pops on Positive ALS Study Results appeared first on InvestorPlace.

NeuroSense Therapeutics (NRSN) Stock Pops on Positive ALS Study Results

Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline in these biomarkers in patients treated in NeuroSense's Phase IIa study with PrimeC New biomarker data in people with ALS validates NeuroSense's clinical strategy CAMBRIDGE, Mass. , June 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study

CAMBRIDGE, Mass , June 22, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group's panel discussion on Innovations in ALS: Exploring New Treatments In Development, which will take place on Tuesday, June 28 th, 2022.

NeuroSense CEO to be Panelist at Maxim Group's Innovations in ALS: Exploring New Treatments In Development on June 28, 2022

Phase IIa study successfully met safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biomarkers PrimeC has Orphan Drug Designation with the FDA and EMA CAMBRIDGE, Mass. , June 1, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC

CAMBRIDGE, Mass. , May 31, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update

Ferenc Tracik, MD to deliver presentation - "From Monotherapy to Combination Therapy: Considering a Paradigm   Shift to Target Complexity of ALS" Phase IIb ALS study for NeuroSense's combination therapy PrimeC expected to commence Q2 2022 CAMBRIDGE, Mass. , May 23, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022

Study conducted under FDA cleared protocol in parallel with international Phase IIb trial expected to commence in Q2 2022 CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS

- Patent valid through 2038 - Phase IIb ALS trial expected to commence H1 2022 CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC

Among the most surprising developments of 2021 was the collapse in consumer confidence and sentiment survey results amidst the strong post-pandemic recovery.

News for NeuroSense Therapeutics Ltd Stock (NRSN)